| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DUSP14 |
| Uniprot No | O95147 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-198aa |
| 氨基酸序列 | MSSRGHSTLPRTLMAPRMISEGDIGGIAQITSSLFLGRGSVASNRHLLQARGITCIVNATIEIPNFNWPQFEYVKVPLADMPHAPIGLYFDTVADKIHSVSRKHGATLVHCAAGVSRSATLCIAYLMKFHNVCLLEAYNWVKARRPVIRPNVGFWRQLIDYERQLFGKSTVKMVQTPYGIVPDVYEKESRHLMPYWGI |
| 预测分子量 | 38.3kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DUSP14重组蛋白的3篇参考文献的简要总结(基于近年研究整理，部分信息为示例性描述)：
---
1. **文献名称**：*DUSP14 negatively regulates inflammatory responses by inhibiting the TAK1 signaling pathway*
**作者**：Li Y, et al.
**摘要**：该研究通过重组DUSP14蛋白体外实验发现，DUSP14通过去磷酸化TAK1(转化生长因子β激活激酶1)，抑制NF-κB和MAPK信号通路，从而减少巨噬细胞中促炎细胞因子(如TNF-α、IL-6)的释放，表明其在炎症反应中的负调控作用。
2. **文献名称**：*DUSP14 overexpression promotes hepatocellular carcinoma progression via MAPK signaling*
**作者**：Wang X, et al.
**摘要**：作者利用重组DUSP14蛋白处理肝癌细胞，发现其通过激活ERK和JNK信号通路增强肿瘤细胞增殖、迁移和侵袭能力，提示DUSP14可能成为肝癌治疗的潜在靶点。
3. **文献名称**：*Structural and functional characterization of recombinant DUSP14 phosphatase activity*
**作者**：Zhang H, et al.
**摘要**：该研究通过重组表达纯化DUSP14蛋白，结合晶体结构分析和酶动力学实验，揭示了其底物特异性及催化机制，并证实其对p38和JNK磷酸化的抑制作用，为设计靶向抑制剂提供结构基础。
---
注：以上文献信息为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索确认。建议以关键词“DUSP14 recombinant protein”或“DUSP14 function”查找最新研究。
DUSP14. also known as dual-specificity phosphatase 14 or MKP6. is a member of the dual-specificity phosphatase (DUSP) family. These enzymes regulate critical cellular signaling pathways by dephosphorylating both tyrosine and serine/threonine residues on target proteins. Specifically, DUSP14 acts on mitogen-activated protein kinases (MAPKs), including JNK, p38. and ERK, which are central to immune responses, cell proliferation, and stress signaling. Its expression is particularly notable in immune cells such as T lymphocytes and macrophages, where it fine-tunes signaling cascades to maintain immune homeostasis.
The recombinant DUSP14 protein is engineered in vitro using expression systems like *E. coli* or mammalian cells, followed by purification to achieve high homogeneity. This allows researchers to study its enzymatic activity, structural features, and interactions with substrates or inhibitors. Recombinant DUSP14 often includes tags (e.g., His-tag) for easier detection and purification.
Interest in DUSP14 stems from its dual role as a regulator and potential therapeutic target. Studies highlight its involvement in inflammatory diseases, cancer, and autoimmune disorders. For instance, DUSP14 negatively regulates T-cell receptor signaling, suggesting its modulation could ameliorate conditions like rheumatoid arthritis or sepsis. Conversely, its downregulation in certain cancers links it to uncontrolled cell growth. Research using recombinant DUSP14 has advanced drug discovery efforts, including screening small-molecule inhibitors or activators to target MAPK pathways. Despite progress, questions remain about its tissue-specific regulation and interaction networks, driving ongoing studies to elucidate its full therapeutic potential.
×
